Structured evidence table for Resveratrol Mood Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resveratrol Mood Randomized Trial | Furthermore, MDD is linked to a higher risk of developing other conditions like diabetes, heart disease, and stroke, which add to its overall impact on health (). | 3 | Zhu Shiyu (2026) | Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy |
| Resveratrol Mood Randomized Trial | Neuroimaging studies have identified key pathological features of MDD, including reduced structural volumes in both cortical and subcortical areas, decreased gray matter volume, and significant alterations in the size and density of microglial cells (,). | 3 | Zhu Shiyu (2026) | Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy |
| Resveratrol Mood Randomized Trial | These changes are also associated with abnormal neurotransmitter regulation and disruptions in gut microbiota (). | 3 | Zhu Shiyu (2026) | Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy |
| Resveratrol Mood Randomized Trial | 1 2 3 4 5 6 7 8 9 10 11 12 Major depressive disorder (MDD) is a prevalent psychiatric condition impacting approximately 185 million individuals worldwide (). | 3 | Zhu Shiyu (2026) | Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy |
| Resveratrol Mood Randomized Trial | Probiotic and Dietary Supplements Intervention in Age-Related Neurodegenerative Disorders | 4 | D’Anniballe De Salles C (2026) | Probiotic and Dietary Supplements Intervention in Age-Related Neurodegenerative Disorders |
Source documents